Asabys Partners

Quibim, headquartered in Valencia, Spain, is a leader in whole-body medical imaging analysis, providing innovative AI-based image processing technologies. Its products, utilized by pharmaceutical companies and research teams globally, focus on extracting quantitative information from radiological images. Quibim Precision®, the company's whole-body imaging ecosystem, supports a variety of applications, from disease detection to monitoring the effectiveness of new treatments. By employing an AI-first approach, Quibim enables partners to accurately identify pathologies across different body parts and imaging modalities, ultimately enhancing the diagnosis of high-incidence illnesses and assessing treatment outcomes. This commitment to leveraging advanced imaging biomarkers contributes significantly to improving human health.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

XRHealth Ltd. is a medical technology company that specializes in developing virtual reality (VR) and augmented reality (AR) solutions for therapeutic applications. Based in Tel Aviv, Israel, XRHealth creates a range of software platforms designed to enhance patient care and address various health-related challenges. Its offerings include VRPhysio for virtual physical therapy, VRReliever for pain management, VRCogni for improving motor function in stroke and dementia patients, and VRPsyc for exposure therapy targeting mental health disorders. Additionally, VRCoordi focuses on improving coordination skills for individuals with conditions such as Parkinson's disease and autism. By integrating immersive technologies, licensed clinicians, and advanced data analytics, XRHealth provides comprehensive telehealth services, enabling patients to receive effective treatment from the comfort of their homes. Founded in 2016, the company aims to innovate healthcare delivery for patients, clinicians, and healthcare professionals alike.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Nuage Therapeutics is a pharmaceutical company which utilizes chemical biology and biomolecular condensation to develop selective drugs that target proteins with disordered regions for challenging indications to improve patient’s life. The focus of the medication is to enhance selective inhibitors of intrinsically disordered proteins involved in challenging indications in order to meet unmet medical needs.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Cara Care is a digital health platform focused on improving gut health through an app designed for patients with chronic gastrointestinal issues. The application enables users to track their dietary habits, including custom dishes and food items from an extensive database, while also recording symptoms such as pain, bloating, and emotional states. This comprehensive approach allows individuals to identify patterns and correlations between their diet and digestive health, empowering them to take control of their well-being. With a user base exceeding 700,000 patients globally, Cara Care combines behavioral, microbial, and nutritional data to offer a holistic alternative to traditional medication for digestive disorders.

Sidekick is a patient-centric digital care platform designed to manage and prevent chronic and lifestyle-related conditions. It offers a scalable solution that enhances healthcare by developing digital health products aimed at empowering patients and digitizing healthcare processes. The platform combines an evidence-based clinical approach with elements of behavioral economics and gamification, creating a more engaging healthcare experience. Sidekick's integrated platform supports multi-chronic condition management and personalized care, facilitating connections between users and clinicians while providing valuable data insights. The company collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve health outcomes.

Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Koa Health B.V., founded in 2018 and based in Amsterdam with additional offices in Barcelona, the United States, and the United Kingdom, develops digital solutions aimed at enhancing mental well-being for employees. The company provides a range of products that are informed by the latest clinical research and technology. Its offerings include the koa foundation application, which supports early symptom management and mild mental health issues, and Mindset, a chat-based platform for private mental health support. Koa Health’s solutions encompass prevention, prediction, and treatment, featuring a library of evidence-based activities designed to address various mental health challenges, such as stress management, sleep improvement, and confidence building. By delivering scalable and affordable care, Koa Health aims to make mental health support accessible and effective for individuals and organizations alike.

Sidekick is a patient-centric digital care platform designed to manage and prevent chronic and lifestyle-related conditions. It offers a scalable solution that enhances healthcare by developing digital health products aimed at empowering patients and digitizing healthcare processes. The platform combines an evidence-based clinical approach with elements of behavioral economics and gamification, creating a more engaging healthcare experience. Sidekick's integrated platform supports multi-chronic condition management and personalized care, facilitating connections between users and clinicians while providing valuable data insights. The company collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve health outcomes.

Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

Origo Biopharma S.L. is a biotechnology company founded in 2017 and headquartered in San Cibrao das Viñas, Spain. The company specializes in the research and development of immunotherapeutic products aimed at treating severe diseases associated with TGF-β signaling dysfunction, particularly in gastrointestinal and lung conditions. Origo Biopharma focuses on developing organ-restricted drugs to meet unmet medical needs related to cancer and fibrosis, striving to provide effective treatments for these challenging health disorders.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.

Cara Care is a digital health platform focused on improving gut health through an app designed for patients with chronic gastrointestinal issues. The application enables users to track their dietary habits, including custom dishes and food items from an extensive database, while also recording symptoms such as pain, bloating, and emotional states. This comprehensive approach allows individuals to identify patterns and correlations between their diet and digestive health, empowering them to take control of their well-being. With a user base exceeding 700,000 patients globally, Cara Care combines behavioral, microbial, and nutritional data to offer a holistic alternative to traditional medication for digestive disorders.

Amelia Virtual Care is a mental health technology company with offices in Barcelona and Mountain View, specializing in a comprehensive virtual reality platform designed for mental health treatment. This platform enables professionals to address a variety of mental health disorders, including phobias, anxiety, and depression. With a workforce of over 60 employees, Amelia has successfully delivered more than 200,000 VR therapy sessions, primarily in the United States, which serves as its main market. The company's innovative platform includes multiple features and user-friendly controls, facilitating effective therapy sessions. Recent financing and a new management team are expected to enhance Amelia's growth and strengthen its clinical evidence and commercial activities.